Gout drugs use and risk of cancer: A case-control study - 15/11/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Concerns have been raised regarding the risk of gout medications to cancer risk. |
• | Having lack of epidemiological evidence, this study shows the association between gout drugs and risk of cancer. |
• | Gout drugs are significantly increased risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer. |
Abstract |
Objective |
Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.
Methods |
We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.
Results |
We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13).
Conclusion |
In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Gout drugs, Breast cancer, Cervical cancer, Allopurinol, Pharmacoepidemiology etc.
Plan
Vol 85 - N° 6
P. 747-753 - décembre 2018 Retour au numéro
Article précédent
- Ultrasonography and detection of subclinical joints and tendons involvements in Systemic Lupus erythematosus (SLE) patients: A cross-sectional multicenter study
- Carine Salliot, Amélie Denis, Emmanuelle Dernis, Vincent Andre, Aleth Perdriger, Jean-David Albert, Saloua Mammou Mraghni, Isabelle Griffoul-Espitalier, Mohamed Hamidou, Benoit Le Goff, Sandrine Jousse Joulin, Thierry Marhadour, Christophe Richez, Nicolas Poursac, Estebaliz Lazaro, Stéphanie Rist, Anca Corondan, Clara Quinten, Virginie Martaillé, Antoine Valéry, Emilie Ducourau
- Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study
- Clotilde Loustau, Nicolas Rosine, Marine Forien, Sébastien Ottaviani, Pierre-Antoine Juge, Frédéric Lioté, Thomas Bardin, Pascal Richette, Philippe Dieudé, Christophe Richez, Bernard Bannwarth, Thierry Schaeverbeke, Hang-Korng Ea, Marie-Elise Truchetet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?